Alkahest Announces

Update research Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration SAN CARLOS, Calif., May 14, 2018 /PRNewswire/ — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on...
On